Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Thoracic Malignancies
•
Medical Oncology
Would you consider switching capmatinib to tepotinib or vice versa due to grade 3 hepatotoxicity in a patient with metastatic NSCLC with MET Exon 14 skipping mutation?
Related Questions
Which patients are you utilizing subcutaneous PD-1/L1 inhibitors instead of the intravenous formulation?
Will you offer lurbinectedin with atezolizumab for patients with ES-SCLC during maintenance if they had brain metastases at baseline?
In light of the 2024 Shkreli Awards, how do you address patient concerns regarding the 240 mg versus 960 mg dose of sotorasib?
How, if at all, are you modifying your practice and clinical workflow for patients receiving checkpoint inhibitors with data showing improved outcomes for patients receiving infusions earlier in the day?
Would you consider using Elahere for patients with FOLR1-positive metastatic lung adenocarcinoma?
When will you select Dato-DXd for patients with EGFR-mutated non-small cell lung cancer?
Is concurrent immuno-radiation therapy a viable treatment option for patients with unresectable, non-metastatic, locally advanced lung cancer, who have high PD-L1 expression and no oncogenic mutations?
Is there evidence supporting the role of SBRT in the management of oligometastatic stage IV NSCLC?
What is your preferred treatment option after tarlatamab for patients with ES-SCLC?
Would you give durvalumab consolidation to a patient with stage III NSCLC with an STK11 mutation?
